LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Home・Aandelen Lijst・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

42.79 -2.22

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

42.14

Max

43.89

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -105M
Winstmarge	-867.293
Werknemers	316
EBITDA	-15M -104M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+28.91% upside

Dividenden
By Dow Jones
Volgende Winsten	5 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-13M 3.3B
Vorige openingsprijs	45.01
Vorige sluitingsprijs	42.79

Nieuwssentiment

By Acuity

50%

158 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.81 / 38.24 Steun & Weerstand

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 mrt 2026, 18:43 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3 mrt 2026, 17:33 UTC

Acquisities, Fusies, Overnames

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3 mrt 2026, 23:45 UTC

Marktinformatie

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3 mrt 2026, 23:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3 mrt 2026, 23:25 UTC

Marktinformatie

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3 mrt 2026, 23:25 UTC

Marktinformatie

Global Energy Roundup: Market Talk

3 mrt 2026, 22:38 UTC

Belangrijke Nieuwsgebeurtenissen

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3 mrt 2026, 22:16 UTC

Winsten

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3 mrt 2026, 22:09 UTC

Winsten

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3 mrt 2026, 22:06 UTC

Winsten

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3 mrt 2026, 22:05 UTC

Winsten

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3 mrt 2026, 22:03 UTC

Winsten

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Tech, Media & Telecom Roundup: Market Talk

3 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

3 mrt 2026, 21:45 UTC

Belangrijke Nieuwsgebeurtenissen

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3 mrt 2026, 21:37 UTC

Winsten

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3 mrt 2026, 21:26 UTC

Belangrijke Nieuwsgebeurtenissen

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3 mrt 2026, 20:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3 mrt 2026, 20:04 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3 mrt 2026, 19:17 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold and Silver Drop as Energy Surges -- Market Talk

3 mrt 2026, 18:43 UTC

Winsten

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3 mrt 2026, 18:29 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Energy Roundup: Market Talk

3 mrt 2026, 18:29 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3 mrt 2026, 18:22 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3 mrt 2026, 18:22 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3 mrt 2026, 18:17 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3 mrt 2026, 18:14 UTC

Winsten

How Long Can Anthropic Play Defense? -- WSJ

3 mrt 2026, 17:41 UTC

Belangrijke Nieuwsgebeurtenissen

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3 mrt 2026, 17:36 UTC

Belangrijke Nieuwsgebeurtenissen

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3 mrt 2026, 17:28 UTC

Acquisities, Fusies, Overnames

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

28.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 56.45 USD 28.91%

Hoogste 66 USD

Laagste 44 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Gebaseerd op 14 analisten die aandelenratings hebben gegeven aan Xenon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

158 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.